MHRA Alert – Codeine Linctus Reclassified to Prescription-Only Medicine

Codeine Linctus Now Prescription-Only

The MHRA has reclassified codeine linctus (codeine oral solutions) from a general sales list (GSL) medicine to a prescription-only medicine (POM). This change follows a public consultation and reflects updated safety considerations for this commonly used cough suppressant.

What You Need to Know

• Codeine linctus can no longer be supplied over-the-counter without a prescription
• The reclassification applies to all codeine oral solution formulations
• This change aligns with existing restrictions on codeine-containing products and aims to improve safety monitoring
• Healthcare professionals should be aware of this change when managing patients with cough or advising on alternatives

Affected Medications

• Codeine linctus (all strengths and formulations)
• Codeine oral solutions

Recommended Actions

For prescribers: Ensure you are aware of this reclassification when considering codeine for cough management. Consider alternative treatments where appropriate, particularly in vulnerable populations.

For pharmacy and dispensing staff: Update your systems to reflect POM status. Patients requesting codeine linctus over-the-counter should be directed to their GP for a prescription if clinically appropriate.

For all responders: Be aware that codeine linctus is no longer available as a GSL product and will require a prescription in future patient encounters.

Further Information

For the full MHRA alert and detailed guidance, visit the MHRA Drug Safety Update.